// App-Quantinova.ai

: Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial

Researchers

Presenter

  • Bruce Trapnell

Principal Investigators

  • Cecilia Ganslandt

  • Inge Tarnow

  • Taneli Jouhikainen

  • Grant Waterer

  • Cliff Morgan

Medical Centers

  • Translational Pulmonary Science Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, United States of America

  • Savara, Inc., Austin, United States of America

  • University of Western Australia, Crawley, Australia

  • Department of Anaesthesia, Royal Brompton Hospital, London, United Kingdom

Locations

  • United States

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Pulmonary alveolar proteinosis

Biomarkers

  • Granulocyte-macrophage-colony stimulating factor

  • Lactate dehydrogenase

Drug/Treatment

  • Molgramostim

  • GM-CSF

  • APAP

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved